Biocon joins forces with Tabuk Pharmaceuticals to bring GLP-1 diabetes drugs to Middle East

Biocon joins forces with Tabuk Pharmaceuticals to bring GLP-1 diabetes drugs to Middle East

In a strategic move to tackle the growing diabetes crisis in the Middle East, Biocon Limited has announced a partnership with Tabuk Pharmaceutical Manufacturing Company. This alliance aims to commercialize Biocon’s Glucagon-like peptide-1 (GLP-1) products across the Middle East, specifically focusing on Saudi Arabia and neighboring regions. GLP-1 products, which are increasingly recognized for their […]

Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal

Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal

Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada’s esteemed specialty pharmaceutical giant. This collaboration aims at the commercialization of Liraglutide, a sophisticated drug-device formulation. This game-changing combination has been curated for the proficient treatment and management of challenges like Type 2 diabetes and […]

Biocon Generics acquires US facility for $7.7m, targets two billion tablet capacity

Biocon Generics acquires US facility for $7.7m, targets two billion tablet capacity

Biocon Limited, a global leader in the biopharmaceutical industry, has made a landmark announcement: its wholly-owned subsidiary, Biocon Generics Inc., has successfully acquired Eywa Pharma Inc.’s oral solid dosage manufacturing facility. Located in Cranbury, New Jersey, the acquisition became effective on September 1, 2023, with a total transaction value of $7.7 million. This marks Biocon […]

Biocon partners with Zentiva for European marketing of Liraglutide

Biocon partners with Zentiva for European marketing of Liraglutide

Biocon Limited has entered into a semi-exclusive partnership with Zentiva, a Czech pharma company for marketing its drug-device combination Liraglutide for the treatment and management of Type 2 diabetes as well as obesity. As per the terms of the agreement, the Indian pharma company will handle Liraglutide’s manufacturing and supply to Zentiva for the commercialization […]

Biocon ties-up with Tabuk to bring specialty generic products in Middle East

Biocon ties-up with Tabuk to bring specialty generic products in Middle East

Indian pharma company Biocon Limited has forged a partnership with Tabuk Pharmaceutical Manufacturing Company to commercialize certain specialty generic medicines in the Middle East. Tabuk Pharmaceutical is a wholly-owned subsidiary of Astra Industrial Group, a pharma company in the Middle East and North Africa (MENA) region. As per the agreement terms, Tabuk Pharmaceuticals will have […]

Biocon, Libbs Farmaceutica team up for launching generic drugs in Brazil

Biocon, Libbs Farmaceutica team up for launching generic drugs in Brazil

Biocon Ltd, an Indian biopharma company, has entered into a partnership with Brazilian pharma company Libbs Farmaceutica for launching generic drugs in Brazil. The company will be represented in the partnership by its fully-owned subsidiary Biocon Pharma. The partnership marks the foray of Biocon’s generic formulations into the Latin American region. It consolidates on the […]

Biocon launches immunosuppressive drug Tacrolimus capsules in US

Biocon launches immunosuppressive drug Tacrolimus capsules in US

Biocon, an Indian biopharma company, has expanded its generic formulations portfolio with the US launch of generic Tacrolimus capsules. Tacrolimus is a calcineurin inhibitor and an immunosuppressant, which was approved last month by the US Food and Drug Administration (FDA) for its use in the treatment of organ transplant patients. In organ transplant patients, the […]